Insulatard, flexpen — Competitive Intelligence Brief

Insulatard, flexpen (Insulatard, flexpen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting insulin (NPH insulin). Area: Diabetes.

marketed Long-acting insulin (NPH insulin) Insulin receptor Diabetes Small molecule

Target snapshot

Insulatard, flexpen (Insulatard, flexpen) — Göteborg University. Insulatard is a long-acting insulin suspension that provides basal insulin coverage by slowly releasing insulin to maintain blood glucose control between meals and overnight.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Insulatard, flexpen TARGET	Insulatard, flexpen	Göteborg University	marketed	Long-acting insulin (NPH insulin)	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting insulin (NPH insulin) class)

1. Göteborg University · 1 drug in this class